Oliverio Welsh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Oliverio Welsh has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Jorge Ocampo-Candiani
Department of Dermatology, Hospital Universitario “Dr. José Eleuterio González” Universidad Autónoma de Nuevo León Monterrey México
13 shared publications Lucio Vera-Cabrera
Department of Dermatology, Dr. Jose Eleuterio Gonzalez University Hospital, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico
10 shared publications- Jesus Alberto Cardenas-De la Garza
Rheumatology Department, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
9 shared publications Esperanza Welsh
Department of Dermatology, Universidad Autónoma de Nuevo León, Hospital Universitario 'Dr. José Eleuterio González', Monterrey, Nuevo Leon, Mexico
6 shared publications- Mario César Salinas Carmona
Departamento de Inmunología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México
6 shared publications - Adrian Cuellar‐Barboza
Department of Dermatology, Hospital Universitario “Dr. José E. González” Universidad Autonoma de Nuevo León Monterrey México
5 shared publications
Latest Publications
- 1 March 2020
- Published by Wiley in Experimental Dermatology
- Vol. 29 (3) , 259-264
Local secretion of stress hormones increases in alopecia areata lesions after treatment with UVA-1 phototherapy
Alopecia areata (AA) is an autoimmune disease of the hair follicle. Keratinocytes of the hair follicle generate an immunosuppressive environment by the local secretion of hormones of the hypothalamic-pituitary-adrenal axis of the skin (skin HPA analog). Our objective was to measure the local production of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and alpha-melanocyte-stimulating hormone (alpha-MSH) in the scalp tissue of patients with AA before and after ultraviolet A1 (UVA-1) phototherapy to determine their role in the pathogenesis of AA and the effect of UVA-1 on the AA hormonal environment. This was a retrospective and descriptive study of skin samples from 22 patients with AA before and after UVA-1 treatment. We compared the changes in the local hormonal environment by measuring CRH, ACTH, type 2 melanocortin receptor (ACTH receptor) and alpha-MSH with immunohistochemical stains. The positivity of MSH was significantly higher (P = .037) in the post-treatment samples compared with the baseline value. ACTH was significantly higher in intensity (P = .032) in the post-treatment samples compared with the initial value. CRH was significantly higher in intensity (P = .013) in baseline samples compared with the final biopsies. The positivity of the ACTH receptor MC2R was not different between the two groups (P = .626). In AA, an interruption in the signalling of CRH could decrease the local concentration of ACTH and MSH, and consequently, the immunosuppressive effect of these hormones. This phenomenon is normalized in the skin treated with UVA-1. A defective signalling system in the cutaneous HPA axis may be involved in the pathogenesis of AA.
- 1 March 2020
- Published by Wiley in Experimental Dermatology
- Vol. 29 (3) , 259-264
Local secretion of stress hormones increases in alopecia areata lesions after treatment with UVA-1 phototherapy
Alopecia areata (AA) is an autoimmune disease of the hair follicle. Keratinocytes of the hair follicle generate an immunosuppressive environment by the local secretion of hormones of the hypothalamic-pituitary-adrenal axis of the skin (skin HPA analog). Our objective was to measure the local production of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and alpha-melanocyte-stimulating hormone (alpha-MSH) in the scalp tissue of patients with AA before and after ultraviolet A1 (UVA-1) phototherapy to determine their role in the pathogenesis of AA and the effect of UVA-1 on the AA hormonal environment. This was a retrospective and descriptive study of skin samples from 22 patients with AA before and after UVA-1 treatment. We compared the changes in the local hormonal environment by measuring CRH, ACTH, type 2 melanocortin receptor (ACTH receptor) and alpha-MSH with immunohistochemical stains. The positivity of MSH was significantly higher (P = .037) in the post-treatment samples compared with the baseline value. ACTH was significantly higher in intensity (P = .032) in the post-treatment samples compared with the initial value. CRH was significantly higher in intensity (P = .013) in baseline samples compared with the final biopsies. The positivity of the ACTH receptor MC2R was not different between the two groups (P = .626). In AA, an interruption in the signalling of CRH could decrease the local concentration of ACTH and MSH, and consequently, the immunosuppressive effect of these hormones. This phenomenon is normalized in the skin treated with UVA-1. A defective signalling system in the cutaneous HPA axis may be involved in the pathogenesis of AA.
- 16 January 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (5) , E228-E229
Leprosy reactions in North‐East Mexico: epidemiology and risk factors for chronic erythema nodosum leprosum
- 16 January 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (5) , E228-E229
Leprosy reactions in North‐East Mexico: epidemiology and risk factors for chronic erythema nodosum leprosum
- 5 August 2019
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 61 (1) , e137-e139
Immunotherapy for resistant and/or severe alopecia areata in a university hospital setting in Northern Mexico
- 5 August 2019
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 61 (1) , e137-e139
Immunotherapy for resistant and/or severe alopecia areata in a university hospital setting in Northern Mexico
- 7 May 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (11) , e395-e396
Diaminodiphenyl‐sulphone: in vitro activity alone and in combination with other antimicrobials against 30 strains of Nocardia brasiliensis
- 7 May 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (11) , e395-e396
Diaminodiphenyl‐sulphone: in vitro activity alone and in combination with other antimicrobials against 30 strains of Nocardia brasiliensis
- 1 March 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 180 (3) , e69
Image Gallery: Multiple disseminated nodules with dysaesthesia in the Mexican–American border
- 1 March 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 180 (3) , e69
Image Gallery: Multiple disseminated nodules with dysaesthesia in the Mexican–American border
- Open Access
- 1 January 2019
- Published by XMLink in Annals of Dermatology
- Vol. 31 (3) , 320-324
Red Scrotum Syndrome Treatment with Pregabalin: A Case Series
Cardenas-de la Garza JA, et al. Ann Dermatol. 2019 Jun;31(3):320-324. https://doi.org/10.5021/ad.2019.31.3.320
- 1 January 2019
- Published by XMLink in Annals of Dermatology
- Vol. 31 (3) , 320-324
Open AccessRed Scrotum Syndrome Treatment with Pregabalin: A Case Series
Cardenas-de la Garza JA, et al. Ann Dermatol. 2019 Jun;31(3):320-324. https://doi.org/10.5021/ad.2019.31.3.320
- 19 November 2018
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 38 (2) , 201-208
Clinical spectrum of Lyme disease
Lyme disease (borreliosis) is one of the most common vector-borne diseases worldwide. Its incidence and geographic expansion has been steadily increasing in the last decades. Lyme disease is caused by Borrelia burgdorferi sensu lato, a heterogeneous group of which three genospecies have been systematically associated to Lyme disease: B. burgdorferi sensu stricto Borrelia afzelii and Borrelia garinii. Geographical distribution and clinical manifestations vary according to the species involved. Lyme disease clinical manifestations may be divided into three stages. Early localized stage is characterized by erythema migrans in the tick bite site. Early disseminated stage may present multiple erythema migrans lesions, borrelial lymphocytoma, lyme neuroborreliosis, carditis, or arthritis. The late disseminated stage manifests with acordermatitis chronica atrophicans, lyme arthritis, and neurological symptoms. Diagnosis is challenging due to the varied clinical manifestations it may present and usually involves a two-step serological approach. In the current review, we present a thorough revision of the clinical manifestations Lyme disease may present. Additionally, history, microbiology, diagnosis, post-treatment Lyme disease syndrome, treatment, and prognosis are discussed.
- 19 November 2018
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 38 (2) , 201-208
Clinical spectrum of Lyme disease
Lyme disease (borreliosis) is one of the most common vector-borne diseases worldwide. Its incidence and geographic expansion has been steadily increasing in the last decades. Lyme disease is caused by Borrelia burgdorferi sensu lato, a heterogeneous group of which three genospecies have been systematically associated to Lyme disease: B. burgdorferi sensu stricto Borrelia afzelii and Borrelia garinii. Geographical distribution and clinical manifestations vary according to the species involved. Lyme disease clinical manifestations may be divided into three stages. Early localized stage is characterized by erythema migrans in the tick bite site. Early disseminated stage may present multiple erythema migrans lesions, borrelial lymphocytoma, lyme neuroborreliosis, carditis, or arthritis. The late disseminated stage manifests with acordermatitis chronica atrophicans, lyme arthritis, and neurological symptoms. Diagnosis is challenging due to the varied clinical manifestations it may present and usually involves a two-step serological approach. In the current review, we present a thorough revision of the clinical manifestations Lyme disease may present. Additionally, history, microbiology, diagnosis, post-treatment Lyme disease syndrome, treatment, and prognosis are discussed.
- 8 October 2018
- Published by Wiley in The Journal of Dermatology
- Vol. 46 (4) , E128-E129
Disseminated Trichosporon asahii infection in a patient with acute myeloid leukemia
- 8 October 2018
- Published by Wiley in The Journal of Dermatology
- Vol. 46 (4) , E128-E129
Disseminated Trichosporon asahii infection in a patient with acute myeloid leukemia
- 1 September 2018
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 154 (9) , 1076-1077
Polymorphic Erythematous Macules and Plaques With Dysesthesia
- 1 September 2018
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 154 (9) , 1076-1077
Polymorphic Erythematous Macules and Plaques With Dysesthesia